Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Aug 31;11:5371–5381. doi: 10.2147/OTT.S170775

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 Gao et al. This work is published and licensed by Dove Medical Press Limited

The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

STARD13 enhances 5-FU sensitivity and cell stemness via inhibiting RhoA activity, and thus YAP translocate from nuclear to cytoplasm.

Notes: (A and B) HCC cells with STARD13 overexpression as well as RhoA or YAP-5SA overexpression were treated with 5-FU, followed by cell viability assay. (C and D) Ki67 mRNA level was detected in cells depicted in (A). (E) The expression of apoptosis executors (cleaved caspase 3 and cleaved PARP) was determined in cells depicted in (A). (F–H) Cell sphere’s size and number were measured and depicted in cells with STARD13 overexpression as well as RhoA or YAP-5SA overexpression. Data were presented as mean ± SD; ^*P<0.05, ^**P<0.01 vs HepG2 or Huh7.

Abbreviations: HCC, hepatocellular carcinoma; STARD13, StAR-related lipid transfer domain 13.

STARD13 enhances 5-FU sensitivity and cell stemness via inhibiting RhoA activity, and thus YAP translocate from nuclear to cytoplasm.

Notes: (A and B) HCC cells with STARD13 overexpression as well as RhoA or YAP-5SA overexpression were treated with 5-FU, followed by cell viability assay. (C and D) Ki67 mRNA level was detected in cells depicted in (A). (E) The expression of apoptosis executors (cleaved caspase 3 and cleaved PARP) was determined in cells depicted in (A). (F–H) Cell sphere’s size and number were measured and depicted in cells with STARD13 overexpression as well as RhoA or YAP-5SA overexpression. Data were presented as mean ± SD; ^*P<0.05, ^**P<0.01 vs HepG2 or Huh7.

Abbreviations: HCC, hepatocellular carcinoma; STARD13, StAR-related lipid transfer domain 13.